Last reviewed 2025-09-05 · How we verify

NCT04939415: MACH19

RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19

Completed Phase 1 Results posted Last updated 5 September 2025

What this trial tests

Phase 1 trial testing mQFPD in Covid19 in 60 participants. Completed in 13 March 2022.

Timeline

1 July 2021

Primary endpoint
27 January 2022

13 March 2022

Quick facts

Lead sponsor	University of California, San Diego
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	1 July 2021
Primary completion	27 January 2022
Estimated completion	13 March 2022
Sites	2 locations across United States

Drugs / interventions tested

mQFPD — full drug profile →
organic brown rice — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

University of California, San Diego

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Total Protein Normal to Abnormal Transition Primary · 14 days

The Normal to Abnormal percentage reflects the percentage of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.

Group	Value	95% CI
Modified Qing Fei Pei Du Tang	4.5
Placebo	4.6

Albumin Normal to Abnormal Transition Primary · 14 days

The Normal to Abnormal percentage reflects the percentage of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.

Group	Value	95% CI
Modified Qing Fei Pei Du Tang	4.5
Placebo	0.0

Alkaline Phosphatase Normal to Abnormal Transition Primary · 14 days

The Normal to Abnormal percentage reflects the percentage of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.

Group	Value	95% CI
Modified Qing Fei Pei Du Tang	0
Placebo	0

AST Normal to Abnormal Transition Primary · 14 days

The Normal to Abnormal percentage reflects the percentage of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.

Group	Value	95% CI
Modified Qing Fei Pei Du Tang	4.8
Placebo	0

ALT Normal to Abnormal Transition Primary · 14 days

The Normal to Abnormal percentage reflects the percentage of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.

Group	Value	95% CI
Modified Qing Fei Pei Du Tang	9.5
Placebo	0

Bilirubin Normal to Abnormal Transition Primary · 14 days

The Normal to Abnormal percentage reflects the percentage of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.

Group	Value	95% CI
Modified Qing Fei Pei Du Tang	0
Placebo	0

Adj. EGFR Normal to Abnormal Transition Primary · 14 days

The Normal to Abnormal percentage reflects the percentage of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.

Group	Value	95% CI
Modified Qing Fei Pei Du Tang	15.0
Placebo	0

Prothrombin Time Normal to Abnormal Transition Primary · 14 days

The Normal to Abnormal percentage reflects the percentage of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.

Group	Value	95% CI
Modified Qing Fei Pei Du Tang	7.1
Placebo	5.6

APTT Normal to Abnormal Transition Primary · 14 days

The Normal to Abnormal percentage reflects the percentage of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.

Group	Value	95% CI
Modified Qing Fei Pei Du Tang	9.5
Placebo	12.5

ESR Normal to Abnormal Transition Primary · 14 days

The Normal to Abnormal percentage reflects the percentage of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.

Group	Value	95% CI
Modified Qing Fei Pei Du Tang	0
Placebo	0

CRP Normal to Abnormal Transition Primary · 14 days

The Normal to Abnormal percentage reflects the percentage of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.

Group	Value	95% CI
Modified Qing Fei Pei Du Tang	0
Placebo	8.3

LDH Normal to Abnormal Transition Primary · 14 days

The Normal to Abnormal percentage reflects the percentage of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.

Group	Value	95% CI
Modified Qing Fei Pei Du Tang	50
Placebo	41.7

Adverse events — posted to ClinicalTrials.gov

Time frame: 14 days. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Modified Qing Fei Pei Du Tang

Serious: 2/24 (8%)

Deaths: 0/24

Placebo

Serious: 0/23 (0%)

Deaths: 0/23

Serious adverse events (2 terms)

Reaction	System	Modified Qing Fei Pei Du T…	Placebo
ER visit	Gastrointestinal disorders	—	—
ER Visit	General disorders	—	—

Most-reported serious reactions: ER visit, ER Visit.

Data from ClinicalTrials.gov NCT04939415 adverse events section.

Sponsor's own description

This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate a 21-herb formula named modified Qing Fei Pai Du Tang (mQFPD) to treat COVID-19-positive outpatients with mild-to-moderate symptoms assigned to self-quarantined and home management. This the study aims to establish the safety and feasibility of the use of mQFPD vs placebo in 66 total subjects. Subsequent trials will evaluate other therapeutics as well as the efficacy of mQFPD in a larger study population.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other University of California, San Diego trials

Trials by the same sponsor.

NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04939415 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 5 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04939415.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

Loading drug intelligence…